In preclinical studies, inhibition of HIF-1α activity has marked effects on tumor growth; inhibitors of HIF-1α have therefore attracted much attention as new therapeutic agents for patients with advanced malignancies, and several clinical studies have been performed [3]. The gene discussed is HIF1A; the disease is neoplasm.